Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.35 |
| ▸ | ACACB | O00763 | 5/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252598 | 0.88 | CNR2 (0.39) | CNR2ACACBAOC3 | |
| SCHEMBL12459040 | 0.83 | ACACB (0.44) | CNR2ACACBAOC3CHRM4 | |
| SCHEMBL22778684 | 0.78 | HRH3 (0.43) | HRH3MAOB | |
| SCHEMBL12525218 | 0.76 | OGA (0.38) | ACACBAOC3 | |
| SCHEMBL19251168 | 0.74 | POLB (0.47) | CNR2HRH3AOC3 | |
| SCHEMBL12457553 | 0.73 | ACACB (0.41) | ACACBAOC3 | |
| SCHEMBL17057373 | 0.71 | AOC3 (0.35) | ACACBAOC3 | |
| SCHEMBL22032079 | 0.70 | AOC3 (0.33) | ACACBAOC3 | |
| SCHEMBL13674841 | 0.70 | ACACB (0.40) | ACACBAOC3 | |
| SCHEMBL15058900 | 0.70 | AOC3 (0.38) | ACACBAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | CNR2 4387/4885HRH3 4648/4885ACACB 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.